Compare LIVN & EXPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVN | EXPO |
|---|---|---|
| Founded | 1987 | 1967 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | 2015 | 1996 |
| Metric | LIVN | EXPO |
|---|---|---|
| Price | $67.15 | $68.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $72.43 | ★ $88.00 |
| AVG Volume (30 Days) | ★ 657.1K | 409.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $582,014,000.00 |
| Revenue This Year | $9.79 | $12.75 |
| Revenue Next Year | $6.63 | $8.50 |
| P/E Ratio | ★ N/A | $32.90 |
| Revenue Growth | N/A | ★ 4.21 |
| 52 Week Low | $34.24 | $63.25 |
| 52 Week High | $71.58 | $83.92 |
| Indicator | LIVN | EXPO |
|---|---|---|
| Relative Strength Index (RSI) | 61.23 | 53.63 |
| Support Level | $61.63 | $64.33 |
| Resistance Level | $67.92 | $70.52 |
| Average True Range (ATR) | 1.96 | 1.97 |
| MACD | 0.42 | 0.49 |
| Stochastic Oscillator | 86.74 | 70.15 |
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.